Publications by authors named "Ivan A Molodtsov"
The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate, poor response to standard treatment, and low virus-specific antibody response after recovery and/or vaccination. To date, there are no data on the safety and efficacy of the combined vector vaccine Sputnik V in patients with CLL. Here, we analyzed and compared the magnitudes of the antibody and T cell responses after vaccination with the Sputnik V vaccine among healthy donors and individuals with CLL with different statuses of preexposure to coronavirus.
View Article and Find Full Text PDFArticle Synopsis
- A study involving 5,340 residents of Moscow investigated the relationship between immune responses (antibodies and T cells) to SARS-CoV-2 and the likelihood of COVID-19 infection.* -
- Results showed that individuals with both high T-cell and antibody responses had the lowest risk of infection, while those with only an antibody response also had a strong protective effect.* -
- The findings highlight that antibody responses are more crucial for protection against SARS-CoV-2 compared to T-cell responses, suggesting potential implications for public health policies related to COVID-19.*
Despite measures taken world-wide, the coronavirus disease 2019 (COVID-19) pandemic continues. Because efficient antiviral drugs are not yet widely available, vaccination is the best option to control the infection rate. Although this option is obvious in the case of COVID-19-naive individuals, it is still unclear when individuals who have recovered from a previous SARS-CoV-2 infection should be vaccinated and whether the vaccination raises immune responses against the coronavirus and its novel variants.
View Article and Find Full Text PDF